Boston Scientific Heart Defibrillators Effective in Heart Failure Patients
Boston Scientific said on Tuesday that its four year study on the effectiveness of cardiac resynchronization defibrillators in slowing the course of heart failure in patients with milder cases has proved successful.
Boston Scientific heart defibrillators also known as CRT-Ds cost about $30,000 each. Heart failure occurs when the heart fails to supply sufficient blood flow to meet the body's needs. Usually, a heart defibrillator is used to monitor the heart rhythm and stop dangerous fast heart rhythms. An implantable cardiac defibrillator or ICD is a small electronic device implanted inside the chest to prevent sudden death from heart failure due to oddly fast heart rhythms.
The study was conducted amongst 1,800 early-stage heart failure patients who already have a basic heart defibrillator. According to the study, the CRT devices when combined with a basic heart defibrillator can reduce the risk of death in heart failure patients by 29%.
According to statistics, up to 5.5 million Americans suffer from heart failure. Incidentally, about 900,000 of all American heart failure patients are in the early stage. This should be good news for both heart failure patients and Boston Scientific, who have long wanted to expand the use of Boston Scientific heart devices.
When contacted to verify the actual rate of deaths in the two groups or information about side effects or the patients' quality of life, the company could not provide any information. Instead, Boston Scientific plans to release more detailed information later this year.
Boston Scientific appreciated the results of the study."We are very encouraged by these initial positive results, and we are hopeful they will eventually lead to a wider population of heart failure patients being treated with CRT-D therapy, “said Fred Colen, a company official.
Standard Boston Scientific heart defibrillators involve two electrical lead wires that extend to the heart's right ventricle. CRT-D devices add a third lead that attaches to the left ventricle, helping it synchronize pumping of the chambers and improve efficiency. The study found that CRT-D devices reduce the symptoms of heart failure.
Use of heart defibrillators grew considerably when Boston Scientific acquired Guidant Corporation in 2006.The Government also played a part when it published a number of studies showing that a heart defibrillator could prevent the most common cause of heart failure such as a stopped heart.
There is no doubt that the study will significantly expand the market for Boston Scientific heart devices including heart defibrillators. In fact, Shares of Boston Scientific rose 6.1 percent to $9.80 after the company released preliminary results of the study.